Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06408350 · ClinicalTrials.gov registry record · NA
Optimal Intervention to Full Viral Suppression: Text Me, Alexis!
A NA study, sponsored by Friends Research Institute.
- Terminated
- Registry status
- NA
- Development phase
- 71
- Enrollment target
NCT06408350: Clinical Trial NA study, sponsored by Friends Research Institute.
NCT06408350 is a NA study that was terminated before completion, run by Friends Research Institute. The registered enrollment target is 71 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06408350, a NA study, was terminated before completion, sponsored by Friends Research Institute.
- TERMINATED
- Registry status
- NA
- Development phase
- 71 participants
- Enrollment target
Study Summary
Text Me, Alexis! is a three-arm randomized controlled trial (RCT) to determine the optimal and most cost-effective intervention for advancing trans women living with HIV to full viral suppression. Participants will be randomized (1:1:1) to Peer Health Navigation (PHN) alone, SMS (text messaging) alone, or PHN+SMS. Participants in the PHN alone and PHN+SMS arms will receive unlimited navigation sessions over 3 months. Participants in the SMS alone and PHN+SMS arms will receive 3 daily theory-based text messages for 90 days for a total of 270 unique scripted messages.
Primary Outcome
HIV virological suppression is defined as the undetectability threshold ˂200 copies/mL. Key indicators of HIV care will be regressed on treatment condition and a series of baseline and time-varying covariates. Responses at each timepoint will be considered nested within an individual, which is necessary to control for the violations of independence that can occur when repeated measurements are taken from the same individual.
Interventions
- BEHAVIORAL Text Me, Alexis!
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2024-04-11 |
| Est. Completion | 2025-03-19 |
| Phase | NA |
Why NCT06408350 stopped before completion
NCT06408350 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 71 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Text Me, Alexis! is the first listed.
NCT06408350 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06408350 about?
NCT06408350 is a clinical study titled "Optimal Intervention to Full Viral Suppression: Text Me, Alexis!". Text Me, Alexis! is a three-arm randomized controlled trial (RCT) to determine the optimal and most cost-effective intervention for advancing trans women living with HIV to full viral suppression. Participants will be randomized (1:1:1) to Peer Health Navigation (PHN) alone, SMS (text messaging) alo...
What is the current status of trial NCT06408350?
This trial is currently terminated. It is a NA study. The enrollment target is 71 participants. The study started on 2024-04-11. Estimated completion is 2025-03-19.
What interventions are being tested in trial NCT06408350?
The interventions under investigation include: Text Me, Alexis! (BEHAVIORAL).
Who is sponsoring clinical trial NCT06408350?
This trial is sponsored by Friends Research Institute, which has 41 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06408350's enrollment target sits among peer trials
71 1102nd of 2000 higher than 898 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05452889 · 71 participants · Early Phase 1
PET Image in PAH Patients
- NCT05766943 · 71 participants · NA
Reduction of Myopotential Interference With Smart Pass in S-ICD Patients
- NCT06229678 · 71 participants · Early Phase 1
Ketones, SGLT2, HFrEF
- NCT06377566 · 71 participants · Phase 2
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI